Profiles

Keywords
Last Name
Institution

Dusan Stefoski

TitleAssociate Professor
InstitutionRush University, Rush Medical College
DepartmentNeurological Sciences
Address
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    My Scopus ID is 6603947979.
    My NIH COMMONS name is DSTEFOSKI.


    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Giovannoni G, Boyko A, Correale J, Edan G, Freedman MS, Montalban X, Rammohan K, Stefoski D, Yamout B, Leist T, Aydemir A, Borsi L, di Cantogno EV. A plain language summary on assessing the long-term effectiveness of cladribine tablets in people living with relapsing multiple sclerosis: The CLASSIC-MS study. Neurodegener Dis Manag. 2023 Aug 03. PMID: 37535336.
      View in: PubMed
    2. Osen A, Stefoski D, Shoemaker T, Kaplan T, Morales FS. Cyclophosphamide for severe acute forms of central nervous system inflammatory disorders. J Neurol Sci. 2023 08 15; 451:120693. PMID: 37300950.
      View in: PubMed
    3. Giovannoni G, Boyko A, Correale J, Edan G, Freedman MS, Montalban X, Rammohan K, Stefoski D, Yamout B, Leist T, Aydemir A, Borsi L, Verdun di Cantogno E. Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY/CLARITY Extension cohort of CLASSIC-MS: An ambispective study. Mult Scler. 2023 05; 29(6):719-730. PMID: 37012898.
      View in: PubMed
    4. Graham E, Shoemaker T, Stefoski D, Kontzialis M, Naumaan A, Garg RK. The rare case of a 20-year-old male with rapidly progressive primary angiitis of the CNS with a good outcome. Neurol Neuroimmunol Neuroinflamm. 2020 09; 7(5). PMID: 32518173.
      View in: PubMed
    5. Gold R, Radue EW, Giovannoni G, Selmaj K, Havrdova EK, Montalban X, Stefoski D, Sprenger T, Robinson RR, Fam S, Smith J, Chalkias S, Giannattasio G, Lima G, Castro-Borrero W. Long-term safety and efficacy of daclizumab beta in relapsing-remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study. J Neurol. 2020 Oct; 267(10):2851-2864. PMID: 32451615.
      View in: PubMed
    6. Stefoski D, Balabanov R, Waheed R, Ko M, Koralnik IJ, Sierra Morales F. Treatment of natalizumab-associated PML with filgrastim. Ann Clin Transl Neurol. 2019 May; 6(5):923-931. PMID: 31139690.
      View in: PubMed
    7. Sierra Morales F, Wright RB, Novo JE, Arvanitis LD, Stefoski D, Koralnik IJ. Glioblastoma in natalizumab-treated multiple sclerosis patients. Ann Clin Transl Neurol. 2017 07; 4(7):512-516. PMID: 28695151.
      View in: PubMed
    8. Gold R, Radue EW, Giovannoni G, Selmaj K, Havrdova E, Stefoski D, Sprenger T, Montalban X, Cohan S, Umans K, Greenberg SJ, Ozen G, Elkins J. Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study. BMC Neurol. 2016 Jul 26; 16:117. PMID: 27461166.
      View in: PubMed
    9. Gold R, Stefoski D, Selmaj K, Havrdova E, Hurst C, Holman J, Tornesi B, Akella S, McCroskery P. Pregnancy Experience: Nonclinical Studies and Pregnancy Outcomes in the Daclizumab Clinical Study Program. Neurol Ther. 2016 Dec; 5(2):169-182. PMID: 27411694.
      View in: PubMed
    10. Guo Y, Lennon VA, Popescu BF, Grouse CK, Topel J, Milone M, Lassmann H, Parisi JE, Pittock SJ, Stefoski D, Balabanov R, Lucchinetti CF. Autoimmune aquaporin-4 myopathy in neuromyelitis optica spectrum. JAMA Neurol. 2014 Aug; 71(8):1025-9. PMID: 24911400.
      View in: PubMed
    11. Tan LA, Kasliwal MK, Muth CC, Stefoski D, Traynelis VC. Is cervical decompression beneficial in patients with coexistent cervical stenosis and multiple sclerosis? J Clin Neurosci. 2014 Dec; 21(12):2189-93. PMID: 25088960.
      View in: PubMed
    12. Giovannoni G, Gold R, Selmaj K, Havrdova E, Montalban X, Radue EW, Stefoski D, McNeill M, Amaravadi L, Sweetser M, Elkins J, O'Neill G. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial. Lancet Neurol. 2014 May; 13(5):472-81. PMID: 24656609.
      View in: PubMed
    13. Havrdova E, Giovannoni G, Stefoski D, Forster S, Umans K, Mehta L, Greenberg S, Elkins J. Disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with daclizumab high-yield process in the SELECT study. Mult Scler. 2014 Apr; 20(4):464-70. PMID: 24022270.
      View in: PubMed
    14. Gold R, Giovannoni G, Selmaj K, Havrdova E, Montalban X, Radue EW, Stefoski D, Robinson R, Riester K, Rana J, Elkins J, O'Neill G. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. Lancet. 2013 Jun 22; 381(9884):2167-75. PMID: 23562009.
      View in: PubMed
    15. Ren Z, Wang Y, Duan T, Patel J, Liggett T, Loda E, Brahma S, Goswami R, Grouse C, Byrne R, Stefoski D, Javed A, Miller SD, Balabanov R. Cross-immunoreactivity between bacterial aquaporin-Z and human aquaporin-4: potential relevance to neuromyelitis optica. J Immunol. 2012 Nov 01; 189(9):4602-11. PMID: 23008451.
      View in: PubMed
    16. Ko MY, Stefoski D, Balabanov R. Indolent course of progressive multifocal leukoencephalopathy during natalizumab treatment in MS. Neurology. 2011 Sep 06; 77(10):1020; author reply 1020. PMID: 21893676.
      View in: PubMed
    17. Ren Z, Wang Y, Tao D, Liebenson D, Liggett T, Goswami R, Clarke R, Stefoski D, Balabanov R. Overexpression of the dominant-negative form of interferon regulatory factor 1 in oligodendrocytes protects against experimental autoimmune encephalomyelitis. J Neurosci. 2011 Jun 08; 31(23):8329-41. PMID: 21653838.
      View in: PubMed
    18. Ren Z, Wang Y, Liebenson D, Liggett T, Goswami R, Stefoski D, Balabanov R. IRF-1 signaling in central nervous system glial cells regulates inflammatory demyelination. J Neuroimmunol. 2011 Apr; 233(1-2):147-59. PMID: 21257209.
      View in: PubMed
    19. Havrdova E, Galetta S, Stefoski D, Comi G. Freedom from disease activity in multiple sclerosis. Neurology. 2010 Apr 27; 74 Suppl 3:S3-7. PMID: 20421571.
      View in: PubMed
    20. Ren Z, Wang Y, Tao D, Liebenson D, Liggett T, Goswami R, Stefoski D, Balabanov R. Central nervous system expression of interferon regulatory factor 1 regulates experimental autoimmune encephalomyelitis. J Neuroimmune Pharmacol. 2010 Jun; 5(2):260-5. PMID: 20177805.
      View in: PubMed
    21. Liggett T, Melnikov A, Tilwalli S, Yi Q, Chen H, Replogle C, Feng X, Reder A, Stefoski D, Balabanov R, Levenson V. Methylation patterns of cell-free plasma DNA in relapsing-remitting multiple sclerosis. J Neurol Sci. 2010 Mar 15; 290(1-2):16-21. PMID: 20064646.
      View in: PubMed
    22. Kaiser CC, Shukla DK, Stebbins GT, Skias DD, Jeffery DR, Stefoski D, Katsamakis G, Feinstein DL. A pilot test of pioglitazone as an add-on in patients with relapsing remitting multiple sclerosis. J Neuroimmunol. 2009 Jun 25; 211(1-2):124-30. PMID: 19446890.
      View in: PubMed
    23. Havrdova E, Galetta S, Hutchinson M, Stefoski D, Bates D, Polman CH, O'Connor PW, Giovannoni G, Phillips JT, Lublin FD, Pace A, Kim R, Hyde R. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol. 2009 Mar; 8(3):254-60. PMID: 19201654.
      View in: PubMed
    24. Burt RK, Loh Y, Cohen B, Stefoski D, Stefosky D, Balabanov R, Katsamakis G, Oyama Y, Russell EJ, Stern J, Muraro P, Rose J, Testori A, Bucha J, Jovanovic B, Milanetti F, Storek J, Voltarelli JC, Burns WH. Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study. Lancet Neurol. 2009 Mar; 8(3):244-53. PMID: 19186105.
      View in: PubMed
    25. Loh Y, Oyama Y, Statkute L, Quigley K, Yaung K, Gonda E, Barr W, Jovanovic B, Craig R, Stefoski D, Cohen B, Burt RK. Development of a secondary autoimmune disorder after hematopoietic stem cell transplantation for autoimmune diseases: role of conditioning regimen used. Blood. 2007 Mar 15; 109(6):2643-548. PMID: 17119125.
      View in: PubMed
    26. Burt RK, Cohen B, Rose J, Petersen F, Oyama Y, Stefoski D, Katsamakis G, Carrier E, Kozak T, Muraro PA, Martin R, Hintzen R, Slavin S, Karussis D, Haggiag S, Voltarelli JC, Ellison GW, Jovanovic B, Popat U, McGuirk J, Statkute L, Verda L, Haas J, Arnold R. Hematopoietic stem cell transplantation for multiple sclerosis. Arch Neurol. 2005 Jun; 62(6):860-4. PMID: 15956156.
      View in: PubMed
    27. Burt RK, Cohen BA, Russell E, Spero K, Joshi A, Oyama Y, Karpus WJ, Luo K, Jovanovic B, Traynor A, Karlin K, Stefoski D, Burns WH. Hematopoietic stem cell transplantation for progressive multiple sclerosis: failure of a total body irradiation-based conditioning regimen to prevent disease progression in patients with high disability scores. Blood. 2003 Oct 01; 102(7):2373-8. PMID: 12842989.
      View in: PubMed
    Stefoski's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (131) concept(s)
    _
    Co-Authors Expand Description
    See all (10) people
    _
    Similar People Expand Description
    See all (60) people
    _
    Same Department Expand Description
    Search Department